Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
107.13
+5.09 (4.99%)
Jun 18, 2026, 4:00 PM EDT - Market closed
Mirum Pharmaceuticals Employees
Mirum Pharmaceuticals had 418 employees as of March 31, 2026. The number of employees increased by 46 or 12.37% since the number was last reported on December 31, 2025.
Employees
418
Change
46
Growth
12.37%
Revenue / Employee
$1,362,701
Profits / Employee
-$1,911,103
Market Cap
6.53B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Mar 31, 2026 | 418 | 46 | 12.37% | 418 | 0 |
| Dec 31, 2025 | 372 | 50 | 15.53% | 369 | 3 |
| Dec 31, 2024 | 322 | 58 | 21.97% | 322 | 0 |
| Dec 31, 2023 | 264 | 68 | 34.69% | 264 | 0 |
| Dec 31, 2022 | 196 | 59 | 43.07% | 196 | 0 |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| PTC Therapeutics | 991 |
| ImmunityBio | 691 |
| Vaxcyte | 507 |
| Rhythm Pharmaceuticals | 414 |
| Immunovant | 315 |
| Scholar Rock Holding | 289 |
| Apogee Therapeutics | 261 |
| Cogent Biosciences | 258 |
MIRM News
- 4 days ago - Mirum Pharmaceuticals price target raised to $146 from $140 at Citizens - TheFly
- 5 days ago - Incyte, Mirum announces Phase 2 results from Cohort 1 of Progress study - TheFly
- 5 days ago - Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva - Business Wire
- 6 days ago - Mirum Pharmaceuticals Slides: Study update presentation - Filings
- 8 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 8 days ago - Mirum Pharmaceuticals price target raised to $150 from $140 at Morgan Stanley - TheFly
- 15 days ago - Incyte, Mirum to present Phase 2 results from PROGRESS study at ENDO 2026 - TheFly
- 15 days ago - Mirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026 - Business Wire